3-二甲氨基-1-(4-甲基苯基)丙醇 | 58574-60-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-二甲氨基-1-(4-甲基苯基)丙醇
• 英文名称: 3-dimethylamino-1-(4-methylphenyl)propanol
• 英文别名: 3-(dimethylamino)-1-(p-tolyl)propan-1-ol；4-methyl-α-(2-dimethyl-aminoethyl)benzyl alcohol；3-dimethylamino-1-(4-methylphenyl)-propanol；1-<4-Methyl-phenyl>-3-dimethylamino-propanol-(1)；(+/-)-3-Dimethylamino-1-hydroxy-1-p-tolyl-propan；1-(4-Methyl-phenyl)-3-dimethylamino-propanol-(1)；3-(dimethylamino)-1-(4-methylphenyl)propan-1-ol
• CAS: 58574-60-0
• 化学式: C₁₂H₁₉NO
• 分子量: 193.289
• InChiKey: NDCBASIYFTYQSG-UHFFFAOYSA-N

物化性质

• 沸点：
  304.3±30.0 °C(Predicted)
• 密度：
  0.998±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-二甲氨基-1-(4-甲基苯基)丙醇 在 2,4-滴二甲胺盐 、 sodium hydride 作用下， 以 苯 为溶剂， 生成
  参考文献：
  名称：

  Duloxetine (Cymbalta™), a dual inhibitor of serotonin and norepinephrine reuptake

  摘要：

  A series of naphthalenyloxy-arylpropylamines have been prepared and are demonstrated to be inhibitors of both serotonin and norepinephrine reuptake. One member of this series, duloxetine (Cymbalta(TM)) has proven to be effective in clinical trials for the treatment of depression. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.079
• 作为产物：
  描述：

  1-(4-甲基苯基)-3-二甲氨基-1-丙酮盐酸盐 在 sodium tetrahydroborate 作用下， 以 甲醇 、 水 为溶剂， 反应 6.0h， 生成 3-二甲氨基-1-(4-甲基苯基)丙醇
  参考文献：
  名称：

  Avramova; Dryanovska; Ilarionov, Pharmazie, 1983, vol. 38, # 7, p. 443 - 444

  摘要：

  DOI：

文献信息

• Synthesis and pharmacological investigation of aralkyl diamine derivatives as potential triple reuptake inhibitors
  作者：Yong-Yong Zheng、Zhi-Jie Weng、Peng Xie、Mei-Yu Zhu、Long-Xuan Xing、Jian-Qi Li

  DOI：10.1016/j.ejmech.2014.08.045

  日期：2014.10

  A series of aralkyl diamine derivatives were designed, synthesized, and evaluated for their triple reuptake inhibitory abilities. Compounds 18c (5-HT, NE, DA, IC50 = 389, 69, 238 nM), 36a (5-HT, NE, DA, IC50 = 378, 477, 247 nM), and 36d (5-HT, NE, DA, IC50 = 501, 206, 357 nM) showed in vivo activities in the rat forced swim test at 5, 10, and 20 mg/kg PO. 36a was identified as the most promising candidate

  设计，合成了一系列芳烷基二胺衍生物，并对其三重再摄取抑制能力进行了评估。化合物18c（5-HT，NE，DA，IC 50  = 389，69，238 nM），36a（5-HT，NE，DA，IC 50  = 378，477，247 nM）和36d（5-HT， NE，DA，IC 50  = 501、206、357 nM）在大鼠强迫游泳试验中以5、10和20 mg / kg PO表现出体内活性。36a被确定为本研究中最有前途的候选人。具体而言，36a对许多中枢神经系统相关靶标的单胺转运蛋白表现出高选择性。此外，36a 在临床前研究中显示出良好的药代动力学性质和可接受的安全性。
• [EN] NOVEL PROCESS FOR THE PREPARATION OF 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES.<br/>[FR] NOUVEAU PROCEDE DE PREPARATION DE 4-ARYL-3-HYDROXYMETHYL-1-METHYLPIPERIDINES
  申请人：NATCO PHARMA LTD

  公开号：WO2004043921A1

  公开（公告）日：2004-05-27

  A novel, improved, and general process for the preparation of 4-aryl-3-hydroxymethyl-1-methylpiperidines is disclosed in the present invention. 4-(4-Fluorophenyl)-3-hydroxymethyl-1-methylpiperidine is a well-known intermediate in making the anti-depressant drug, paroxetine ((-)-trans-4-p-fluorophenyl-3-(3',4'-methylenedioxy-phenoxymethyl)piperidine). Novel N-methyl-N-[3-(4-substitutedphenyl (F, Me, OMe))-3-hydroxy]propylamines are prepared from the Mannich salts such as 3-dimethylamino- or 3-(N-methyl-N-benzylamino)-4'-substituted (F, Me, OMe) propiophenone hydrochlorides by conventional methods. The N-methyl-N-[3-(4-substitutedphenyl (H, F, Me, OMe))-3-hydroxy]propylamines thus obtained are reacted with ethyl or methyl acrylate to get the corresponding Michael addition products. The hydroxy group present in the Michael addition products is converted into a facile leaving group and treated with a strong base to get 4-aryl-N-methylpiperidine-3-carboxylates via the intramolecular cyclization in good yields. Reduction of the ester group present in these piperidine-3-carboxylates gave the title compounds as crystalline solids. Present process is easily adaptable for commercial preparation of the paroxetine intermediate (4-(4-fluorophenyl)-3-hydroxymethyl-1-methylpiperidine).

  本发明揭示了一种新颖的、改进的、通用的制备4-芳基-3-羟甲基-1-甲基哌啶的方法。4-(4-氟苯基)-3-羟甲基-1-甲基哌啶是制造抗抑郁药物帕罗西汀((-)-trans-4-p-氟苯基-3-(3',4'-亚甲二氧基苯氧甲基)哌啶)的已知中间体。新型的N-甲基-N-[3-(4-取代苯基(F，Me，OMe))-3-羟基]丙胺可通过常规方法从Mannich盐制备而来，例如3-二甲氨基或3-(N-甲基-N-苄基氨基)-4'-取代(F，Me，OMe)丙酮盐酸盐。因此获得的N-甲基-N-[3-(4-取代苯基(H，F，Me，OMe))-3-羟基]丙胺与乙基或甲基丙烯酸酯反应，得到相应的Michael加成产物。Michael加成产物中存在的羟基转化为容易离去的基团，并用强碱处理，通过分子内环化以良好的产率得到4-芳基-N-甲基哌啶-3-羧酸酯。这些哌啶-3-羧酸酯中存在的酯基还原后，得到了晶体固体的目标化合物。目前的方法易于用于商业制备帕罗西汀中间体(4-(4-氟苯基)-3-羟甲基-1-甲基哌啶)。
• UII-modulating compounds and their use
  申请人：Luthman Kristina Ingrid

  公开号：US20070043104A1

  公开（公告）日：2007-02-22

  Disclosed herein are novel aromatic-containing compounds and methods for using various aromatic-containing compounds for treatment and prevention of diseases and disorders related to the Urotensin II receptor.

  本文披露了新型芳香族含有化合物及其在治疗和预防与Urotensin II受体相关的疾病和疾病障碍方面的应用方法。
• WO2006/135694
  申请人：——

  公开号：——

  公开（公告）日：——
• Design, parallel synthesis and SAR of novel urotensin II receptor agonists
  作者：Fredrik Lehmann、Lisa Lake、Erika A. Currier、Roger Olsson、Uli Hacksell、Kristina Luthman

  DOI：10.1016/j.ejmech.2006.09.015

  日期：2007.2

  A 30-membered library of amides based on the potent urotensin II (UII) receptor agonist FL104, has been synthesized from ten different carboxylic acids and three amines. A synthetic protocol producing the amides in 47-98% yield has been developed in which the purification involved only extractions and in a few cases filtration through an ion-exchange resin. It was found that 5 mg of starting material was enough to obtain reproducible results and excellent purities. Thus, the procedure is estimated to be transferable to fully automated systems. The synthesized compounds were evaluated for their Ull receptor agonistic activities using a cell-based assay (R-SAT). The most active compounds were the 4-trifluoromethylcinnamic amides of 1-(4-chlorophenyt)-3-dimethylamino-propylamine and 1-(2-naphthyl)-3-dimethylamino-propylamine, both showed EC50 values of 130 nM. (c) 2006 Elsevier Masson SAS. All rights reserved.